MyopiaChildren's healthDevice
What this study is
The aim of this study is evaluate and compare the mobility performance of children in daily activities while wearing standard single vision spectacle lenses and myopia control spectacle lenses.
What's being tested
- Novel spectacle lens design
Intervention · DEVICE
- Spectacle lenses
Intervention · DEVICE
Both interventions
Use of lenses to correct myopia and may reduce the rate of progression of juvenile myopia
Study details
- Official title
- Mobility Performance in Daily Activities Among Children Wearing Single Vision and Myopia Control Spectacle Lenses
- Sponsor
- SightGlass Vision, Inc.
- Conditions
- Myopia · Myopia Progression · Juvenile Myopia
- Enrolling
- 40 people
- Starts
- 2026-02-02
- Est. completion
- 2028-07-01
- Design
- Single-blind, randomized, crossover
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 6 Years – 12 YearsSex ALLHealthy volunteers AcceptedYou may qualify if
- Are between the ages of 6 and 12 years of age (inclusive) at the time of informed consent/assent.
- Can achieve a corrected visual acuity of 20/20 best-corrected (or equivalent logMAR).
- Have undergone a self-reported oculo-visual examination within the past two years.
- Have no active ocular disease.
- Are willing and able to adhere to instructions, study procedures, and maintain the appointment schedule.
- Have not previously worn or participated in myopia control contact lenses for more than one month and are not currently undergoing any form of myopia control treatment.
- The subject's parent(s) or legal guardian(s) must read, understand, and sign the Statement of Informed Consent and receive a fully executed copy of the form.
You can't join if
- Have any systemic disease that affects ocular health.
- Are currently using or have used, within the past 7 days, any systemic or topical medications that may impact ocular health.
- Are currently using or have used any topical ophthalmic agents with anti-muscarinic properties within 7 days prior to enrollment or at any point during the study. This includes, but is not limited to, atropine, scopolamine, pirenzepine, tropicamide, cyclopentolate, and homatropine.
- Have used any oral agents with anti-muscarinic properties for a chronic period (2 months or more) or short-term (within 7 days prior to enrollment). This includes, but is not limited to, gastrointestinal anti-spasmodic medications containing atropine, hyoscyamine, and dicyclomine.
- Have known developmental delays.
- Have participated in another clinical study in the last 7 days
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
1
Study locations (1)
1 openMidwestern University Arizona College of Optometry
Glendale, Arizona, United States
- Javier Gantes-Nunez · Contact
Recruiting
Study team
Sponsor
SightGlass Vision, Inc.
Study ID CPRO-2507-001
Have questions? The contacts above can answer them before you apply.
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.